Skip to Content
Print Share

Medications for Non-Small Cell Lung Cancer

Other names: Cancer, Lung, Non-Small Cell; Lung Cancer, Non-Small Cell; NSCLC

About Non-Small Cell Lung Cancer:  Non-Small Cell Lung Cancer is cancer of the lung which is not small cell carcinoma.

Drugs Used to Treat Non-Small Cell Lung Cancer

The following list of medications are in some way related to, or used in the treatment of this condition.

Drug name Rx / OTC Pregnancy CSA Alcohol Reviews Rating Popularity
Tarceva D N 39 reviews
8.8

Generic name: erlotinib systemic

Drug class: EGFR inhibitors

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

Alimta D N 1 review
8.0

Generic name: pemetrexed systemic

Drug class: antimetabolites

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

Avastin C N 1 review
8.0

Generic name: bevacizumab systemic

Drug class: VEGF/VEGFR inhibitors

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

Tagrisso N 7 reviews
6.0

Generic name: osimertinib systemic

Drug class: EGFR inhibitors

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

Iressa D N 8 reviews
8.9

Generic name: gefitinib systemic

Drug class: EGFR inhibitors

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

Opdivo N 27 reviews
4.2

Generic name: nivolumab systemic

Drug class: anti-PD-1 monoclonal antibodies

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

cisplatin D N Add review
0.0

Generic name: cisplatin systemic

Drug class: alkylating agents

For consumers: dosage, interactions,

For professionals: A-Z Drug Facts, AHFS DI Monograph, Prescribing Information

erlotinib D N 39 reviews
8.8

Generic name: erlotinib systemic

Brand name:  Tarceva

Drug class: EGFR inhibitors

For consumers: dosage, interactions,

For professionals: A-Z Drug Facts, AHFS DI Monograph, Prescribing Information

Keytruda D N 50 reviews
3.6

Generic name: pembrolizumab systemic

Drug class: anti-PD-1 monoclonal antibodies

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

pemetrexed D N 2 reviews
9.0

Generic name: pemetrexed systemic

Brand name:  Alimta

Drug class: antimetabolites

For consumers: dosage, interactions,

For professionals: A-Z Drug Facts, AHFS DI Monograph, Prescribing Information

Xalkori D N 4 reviews
9.3

Generic name: crizotinib systemic

Drug class: multikinase inhibitors

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

Gemzar D N Add review
0.0

Generic name: gemcitabine systemic

Drug class: antimetabolites

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

Abraxane D N 1 review
1.0

Generic name: paclitaxel protein-bound systemic

Drug class: mitotic inhibitors

For consumers: dosage, interactions, side effects

Taxotere D N Add review
0.0

Generic name: docetaxel systemic

Drug class: mitotic inhibitors

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

nivolumab N 40 reviews
4.8

Generic name: nivolumab systemic

Brand name:  Opdivo

Drug class: anti-PD-1 monoclonal antibodies

For consumers: dosage, interactions,

For professionals: A-Z Drug Facts, AHFS DI Monograph

Tecentriq N Add review
0.0

Generic name: atezolizumab systemic

Drug class: anti-PD-1 monoclonal antibodies

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

bevacizumab C N 1 review
8.0

Generic name: bevacizumab systemic

Brand names:  Avastin, Mvasi, Zirabev

Drug class: VEGF/VEGFR inhibitors

For consumers: dosage, interactions,

For professionals: A-Z Drug Facts, AHFS DI Monograph

Navelbine D N Add review
0.0

Generic name: vinorelbine systemic

Drug class: mitotic inhibitors

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

paclitaxel D N 1 review
7.0

Generic name: paclitaxel systemic

Drug class: mitotic inhibitors

For consumers: dosage, interactions,

For professionals: A-Z Drug Facts, AHFS DI Monograph, Prescribing Information

gefitinib D N 8 reviews
8.9

Generic name: gefitinib systemic

Brand name:  Iressa

Drug class: EGFR inhibitors

For consumers: dosage, interactions,

For professionals: A-Z Drug Facts, AHFS DI Monograph

Gilotrif D N 1 review
10

Generic name: afatinib systemic

Drug class: multikinase inhibitors

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

Trexall X N X Add review
0.0

Generic name: methotrexate systemic

Drug class: antimetabolites, antirheumatics, antipsoriatics, other immunosuppressants

For consumers: dosage, interactions, side effects

For professionals: Prescribing Information

crizotinib D N 5 reviews
9.5

Generic name: crizotinib systemic

Brand name:  Xalkori

Drug class: multikinase inhibitors

For consumers: dosage, interactions,

For professionals: A-Z Drug Facts, AHFS DI Monograph

methotrexate X N X Add review
0.0

Generic name: methotrexate systemic

Brand name:  Trexall

Drug class: antimetabolites, antirheumatics, antipsoriatics, other immunosuppressants

For consumers: dosage, interactions,

For professionals: A-Z Drug Facts, AHFS DI Monograph, Prescribing Information

Alecensa N 1 review
9.0

Generic name: alectinib systemic

Drug class: multikinase inhibitors

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

Learn more about Non-Small Cell Lung Cancer

IBM Watson Micromedex

Symptoms and treatments

Drugs.com Health Center

Legend

Rx Prescription Only
OTC Over the Counter
Rx/OTC Prescription or Over the Counter
Off Label This medication may not be approved by the FDA for the treatment of this condition.
Pregnancy Category
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits.
N FDA has not classified the drug.
Controlled Substances Act (CSA) Schedule
N Is not subject to the Controlled Substances Act.
1 Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision.
2 Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence.
3 Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence.
4 Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3.
5 Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4.
Alcohol
X Interacts with Alcohol.

Browse Treatment Options

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps